Critical Supply Gap: FDA Adds Neurosurgical Patties to Shortage List, Warning of Disruptions Through 2026

Published: May 7, 2026

SILVER SPRING, MD — The U.S. Food and Drug Administration (FDA) has officially added neurosurgical patties, sponges, and strips to its Medical Device Shortages List, a move that signals significant stress for surgical departments across the nation. The agency warned on Wednesday, May 6, 2026, that supply chain disruptions for these essential surgical tools are expected to persist through at least the end of the year. The shortage, primarily triggered by a major product recall in March, has left neurosurgeons and hospital administrators scrambling to implement conservation strategies for procedures where precision is measured in millimeters.

The “Tiny Towels” of the Operating Room

To the layperson, a “neurosurgical pattie”—often referred to in the OR as a “cottonoid”—might look like a simple scrap of fabric. However, in the high-stakes environment of brain and spinal surgery, these sterile, absorbent pads are indispensable.

Made from compressed cotton or specialized synthetic blends, these patties are designed to be non-adherent, meaning they won’t stick to fragile neural tissue. Surgeons use them to:

• Manage Fluids: Absorb blood and cerebrospinal fluid to maintain a clear line of sight.

• Protect Tissue: Act as a gentle barrier between surgical instruments and sensitive brain structures.

• Retract Gently: Assist in holding back delicate tissue without causing mechanical trauma.

“In neurosurgery, visibility isn’t just a convenience; it’s a safety requirement,” says Dr. Elena Vasquez, a neurosurgeon at Johns Hopkins Hospital. “These patties allow us to manage the microscopic surgical field. Without them, the risk of accidental injury to a blood vessel or a nerve increases significantly.”

The Catalyst: A Major Recall and Endotoxin Risks

The current crisis was largely set in motion on March 13, 2026, when Medline Industries, a dominant supplier in the market, issued a voluntary recall of its branded neuro sponge products. The recall affected single sterile, kitted sterile, and bulk non-sterile items

The issue stemmed from an internal review that identified elevated endotoxin levels in the products. Endotoxins are bacterial toxins that, if introduced into the central nervous system during surgery, can trigger a severe inflammatory response. Clinical consequences can include:

• High fever and nausea.

• Febrile responses.

• Hypotension (dangerously low blood pressure).

• Localized inflammation requiring secondary medical or surgical intervention.

The FDA classified this as a Class II recall, suggesting that while the risk of serious permanent injury is relatively low, the potential for adverse health consequences is significant enough to warrant a complete removal from the market. As of May 2026, Medline has not provided a definitive timeline for when these products will return to hospital shelves.

A Fragile Supply Chain Under Pressure

The neurosurgical patty market is highly specialized, with only a handful of manufacturers, such as DeRoyal and American Surgical, capable of meeting the rigorous standards for intracranial use. When a major player like Medline exits the market abruptly, the remaining suppliers are often unable to absorb the sudden surge in demand.

“This is a high-risk, low-frequency product,” explains Karen Niven, Senior Director of Clinical Value Analysis at Premier, a leading healthcare improvement company. “Because these tools are so specialized for brain and spine surgeries, there aren’t many ‘off-the-shelf’ alternatives that a surgeon can just swap in without preparation.

The FDA’s data suggests that the shortage is exacerbated by a “shortage or discontinuance of a component, part, or accessory,” indicating that the issues may run deeper into the raw material layers of the supply chain.

Strategic Conservation: What Hospitals Are Doing

In a Letter to Health Care Providers issued yesterday, the FDA outlined a series of “mitigation strategies” to stretch existing supplies. The agency is urging medical facilities to:

1. Prioritize Cases: Reserve neurosurgical patties for essential procedures, such as intracranial surgeries, tumor resections, and aneurysm clippings.

2. Inventory Control: Centralize supplies within hospital systems to prevent “stockpiling” at individual workstations.

3. Aseptic Discipline: Encourage surgical teams to open packages only when absolutely necessary to avoid wasting sterile units.

4. Explore Substitutes: While few direct substitutes exist, some surgeons may use alternative gelatin-based sponges for minor retraction, though these do not offer the same level of absorbency or tissue protection.

Public Health Impact and Patient Risks

The implications of this shortage extend beyond the operating room. With approximately 30,000 brain aneurysm ruptures occurring annually in the U.S. and a 53% rise in primary brain tumor surgeries over the last few decades, the demand for these devices is constant.

For patients, the shortage may lead to the postponement of elective or non-emergency neurosurgeries. While emergency “life-or-death” cases will remain the priority, patients awaiting spinal decompressions or certain tumor biopsies may face longer wait times.

“We are entering a period where ‘just-in-time’ inventory is no longer a viable strategy for hospitals,” says Dr. Raj Patel, a supply chain analyst at the ECRI Institute. “We have seen similar disruptions with dialysis lines and oxygenators recently. It highlights a systemic vulnerability in how we produce and distribute critical medical hardware.”

Looking Ahead to 2026

The FDA is currently collaborating with other manufacturers to ramp up production and is exploring the possibility of expedited reviews for new suppliers. However, the rigorous sterilization and testing processes required for neurosurgical devices mean that “ramping up” is a slow process.

For now, the medical community is being asked to report any supply interruptions or adverse events related to the shortage to the FDA’s MedWatch program. As the healthcare industry navigates this two-year disruption, the focus remains on ensuring that when a surgeon enters the operating room for a critical brain procedure, they have the tools necessary to protect the patient’s most vital organ.

References

• https://www.reuters.com/legal/litigation/us-fda-flags-shortage-neurosurgical-pads-sponges-expects-disruption-through-2026-2026-05-06/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.